At the BR1DGE symposium at IDS 2024, leading experts shared new insights on the mechanisms driving autoimmune type 1 diabetes (T1D), emphasizing the benefits of genetic risk scoring, and the latest biomarker research.
This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.